A Phase I, Single-Center, Randomised, Double-Blind, Placebo-Controlled Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7325 in Healthy Male Japanese Subjects.
Phase of Trial: Phase I
Latest Information Update: 23 Mar 2009
At a glance
- Drugs AZD 7325 (Primary)
- Indications Anxiety disorders
- Focus Adverse reactions
- Acronyms JSAD
- Sponsors AstraZeneca
- 17 Mar 2009 Actual patient number (48) added as reported by ClinicalTrials.gov.
- 17 Mar 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
- 17 Mar 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.